Recent developments in topical thrombins

Summary

Managing blood loss is part of the surgeon’s responsibility during surgical procedures, and a variety of therapeutic strategies are available to help accomplish this. Topical haemostatic agents are among the agents used to control surgical bleeding and locally arrest blood flow. Bovine thrombin is a commonly used topical haemostatic agent; however, its use has been associated with potential risks, including well-documented cases of antibodymediated coagulopathy. This coagulopathy develops as a consequence of antibody formation directed against bovine thrombin, other bovine coagulation proteins, and their human orthologs. The fact that a coagulopathy can result in association with the use of bovine plasma-derived thrombin preparations prompted the FDA to require pharmaceutical companies to place a black-box warning in their prescribing information for products containing bovine plasma-derived thrombin. Recently, human plasma-derived thrombin and recombinant human thrombin have been approved by the FDA with the expectation that they will be less immunogenic than the bovine-derived product. In clinical studies, purified human plasma-derived thrombin and recombinant thrombin have demonstrated equivalent efficacy and safety, with improved immunogenicity profiles compared with bovinederived thrombin agents. Well-designed and adequately powered clinical trials should be conducted to indicate whether human thrombin products would improve the risk-benefit and costbenefit profiles for surgeries complicated by excessive bleeding.

Keywords

Bovine - coagulopathy - haemostasis - recombinant - thrombin

• References

• 1 Adams GL, Manson RJ, Turner I. et al. The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin North Am 2007; 21: 13-24.
• 2 Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006; 32 (Suppl. 01) 98-110.
• 3 Ferraris VA, Ferraris SP, Saha SP. et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83 (05) Suppl S27-86.
• 4 Gabay M. Absorbable hemostatic agents. Am J Health Syst Pharm 2006; 63: 1244-1253.
• 5 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-2311.
• 6 Spotnitz WD. Active and mechanical hemostatic agents. Surgery 2007; 142 (04) Suppl S34-38.
• 7 Bishop PD, Lewis KB, Schultz J. et al. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. Semin Thromb Hemost 2006; 32 (Suppl. 01) 86-97.
• 8 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-1389.
• 9 Hutchison H. The Chemistry of Blood Coagulation [book review]. J Clin Pathol 1958; 11: 460.
• 10 Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106: 2605-2612.
• 11 Bjorses K, Holst J. Various local hemostatic agents with different modes of action; an in vivo comparative randomized vascular surgical experimental study. Eur J Vasc Endovasc Surg 2007; 33: 363-370.
• 12 Rapaport SI, Zivelin A, Minow RA. et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97: 84-91.
• 13 Nelson PA, Powers JN, Estridge TD. et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res 2001; 58: 710-719.
• 14 Kajitani M, Ozdemir A, Aguinaga M. et al. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 2000; 15: 378-382.
• 15 Schoenecker JG, Johnson RK, Fields RC. et al. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 2003; 197: 580-590.
• 16 Chapman W, Weaver F, Alexander A. Reply. J Am Coll Surg 2008; 206: 199-200.
• 17 Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J Reprod Med 2001; 46: 909-912.
• 18 Crow SS, Sullivan VV, Aysola AE. et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg 2007; 83: 1547-1549.
• 19 Sarfati MR, Dilorenzo DJ, Kraiss LW. et al. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004; 18: 349-351.
• 20 Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42: 18-26.
• 21 Albala DM, Lawson JH. Recent clinical and investigational applications of fibrin sealant in selected surgical specialties. J Am Coll Surg 2006; 202: 685-697.
• 22 Regan F, Taylor C. Blood transfusion medicine. Br Med J 2002; 325: 143-147.
• 23 Williamson LM, Lowe S, Love EM. et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. Br Med J 1999; 319: 16-19.
• 24 DeVeau I, Dabbah R, Sutton S. The USP perspective to minimize the potential risk of TSE infectivity in bovine-derived article used in the manufacture of medical products. Pharmacopeial Forum 2004; 30: 1911-1921.
• 25 Diomede L, Sozzani S, Luini W. et al. Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes. Biochem J 1996; 320: 563-570.
• 26 CBER. Center for Biologics Evaluation and Research. Food and Drug Administration. 2002
• 27 Cordier C, Bencsik A, Philippe S. et al. Transmission and characterization of bovine spongiform encephalopathy sources in two ovine transgenic mouse lines (TgOvPrP4 and TgOvPrP59). J Gen Virol 2006; 87: 3763-3771.
• 28 Nonno R, Di Bari MA, Cardone F. et al. Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog 2006; 02: e12.
• 29 Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13: 320-328.
• 30 Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 01: 457-462.
• 31 Garvey MB. Porcine factor VIII in the treatment of high-titre inhibitor patients. Haemophilia 2002; 08 (Suppl. 01) 5-8 discussion 28-32..
• 32 Gribble J, Garvey MB. Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII. Haemophilia 2000; 06: 482-485.
• 33 Schoenecker JG, Hauck RK, Mercer MC. et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. J Clin Immunol 2000; 20: 434-444.
• 34 Ortel TL, Mercer MC, Thames EH. et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96.
• 35 Banninger H, Hardegger T, Tobler A. et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993; 85: 528-532.
• 36 Dorion RP, Hamati HF, Landis B. et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998; 122: 887-894.
• 37 Chouhan VD, De La Cadena RA, Nagaswami C. et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997; 77: 343-349.
• 38 Ortel TL, Charles LA, Keller FG. et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45: 128-135.
• 39 Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989; 111: 631-634.
• 40 Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-2016.
• 41 Carroll JF, Moskowitz KA, Edwards NM. et al. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb Haemost 1996; 76: 925-931.
• 42 Cmolik BL, Spero JA, Magovern GJ. et al. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 1993; 105: 222-228.
• 43 Terrab A, Pawlak D, Spaay P. et al. Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost 2008; 14: 135-140.
• 44 Doria C, Fischer CP, Wood CG. et al. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008; 24: 785-794.
• 45 Sands JJ, Nudo SA, Ashford RG. et al. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 2000; 35: 796-801.
• 46 Weaver FA, Lew W, Granke K. et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 2008; 47: 1266-1273.
• 47 Crean SM, Michels SL, Reynolds MW. Exogenous bovine thrombin as a biomarker of exposure and outcome. Expert Rev Mol Diagn 2008; 08: 651-661.
• 48 Berguer R, Staerkel RL, Moore EE. et al. Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports. J Trauma 1991; 31: 408-411.
• 49 Christie RJ, Carrington L, Alving B. Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery 1997; 121: 708-710.
• 50 Lollar P. Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor. J Thromb Haemost 2005; 03: 1385-1391.
• 51 Feinstein DI. Acquired inhibitors of factor V. Thromb Haemost 1978; 39: 663-674.
• 52 Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Am J Med 2005; 118: 805.
• 53 Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer 2007; 49: 1025-1029.
• 54 Poynton AR, Nelson MC, McCance SE. et al. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine 2003; 28: E221-223.
• 55 Chapman WC, Singla N, Genyk Y. et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007; 205: 256-265.
• 56 Bitton B. Recombinant human thrombin (Recothrom-ZymoGenetics, Inc. University of Utah Hospitals and Clinics; New Drug Bulletin: 2008
• 57 Su Z, Izumi T, Thames EH. et al. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 2002; 139: 349-356.
• 58 Kapoor A, Cortese Hassett A, Bontempo F. Lack of response bleeding from aquired factor V inhibitor to recombinant human factor VIIa concentrate. Blood (American Society of Hematology Annual Meeting Abstracts). 2005 106. Abstract 4099.
• 59 Lawson JH, Lynn KA, Vanmatre RM. et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005; 79: 1037-1038.
• 60 Shah AK, Moreno-Aspitia A. Acquired factor V inhibitor and single exposure to autologous growth factor. Thromb Res 2005; 116: 87-89.
• 61 Caers J, Reekmans A, Jochmans K. et al. Factor V inhibitor after injection of human thrombin (Tissucol) into a bleeding peptic ulcer. Endoscopy 2003; 35: 542-544.